Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 11INDUSTRY 6NIH 3NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 39Breast 10Gynecologic 3Endocrine 2Thoracic 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Uterine Cervical Neoplasms 2Ovarian Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Cisplatin 63Paclitaxel 56Carboplatin 38Taxes 24Radiotherapy 21Gemcitabine 16Brachytherapy 15Filgrastim 14Doxorubicin 13Topotecan 12Platinum 121,2-diaminocyclohexaneplatinum II citrate 12Docetaxel 11Radiation 7Granulocyte Colony-Stimulating Factor 7Chemotherapy, Adjuvant 7pegfilgrastim 6Surgical Procedures, Operative 6Radiotherapy, Intensity-Modulated 6Polymerase Chain Reaction 6Ifosfamide 6Etoposide 6Watchful Waiting 5Radiotherapy, Conformal 5Pemetrexed 5Gene Expression Profiling 5Fluorouracil 5Celecoxib 5Amifostine 5Observation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Capecitabine × Gynecologic × Clear all
NCT00039442 2017-08-24

Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer

GOG Foundation

Phase 2 Completed
21 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT00016926 2013-05-27

Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

GOG Foundation

Phase 2 Completed
Gynecologic

Uterine Cervical Neoplasms

NCT00006812 2013-04-11

Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

GOG Foundation

Phase 2 Terminated
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡